Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study
Authors
Keywords
-
Journal
BMC Nephrology
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-16
DOI
10.1186/s12882-019-1348-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
- (2016) Hermann Haller et al. CURRENT HYPERTENSION REPORTS
- Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
- (2016) Nathan R. Hill et al. PLoS One
- Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials
- (2015) Khai P Ng et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- The double challenge of resistant hypertension and chronic kidney disease
- (2015) Patrick Rossignol et al. LANCET
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
- (2015) Bryan Williams et al. LANCET
- Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Nephrology
- Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort
- (2015) Sascha Abbas et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. DIABETES CARE
- Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure
- (2014) Javaid Iqbal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy
- (2013) Patrick Rossignol et al. Circulation-Heart Failure
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients
- (2012) Kidney International Supplements
- Blood Pressure Control in CKD Patients: Why Do We Fail to Implement the Guidelines?
- (2010) Gavin J. Becker et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started